Calliditas Therapeutics (CALT) reported data from the proof-of-concept Phase 2 trial evaluating setanaxib, the company's lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck. The analysis showed statistically significant improvements in progression-free survival, as well as in overall survival, with statistically significant changes in tumor biology consistent with the mechanism of action of setanaxib.The company said it is conducting additional clinical trials with setanaxib and will read out its Phase 2 trial in primary biliary cholangitis in third quarter of 2024 and is expecting the investigator led Phase 2 trial in idiopathic pulmonary fibrosis to provide top line data in fourth quarter of 2024.

Calliditas Therapeutics（CALT）报告了来自概念验证2期试验的数据，该试验评估了该公司的铅氮氧化物酶抑制剂西他昔布与派姆单抗联合治疗头颈部鳞状细胞癌患者。分析显示，无进展生存期和总生存期有统计学意义上的显着改善，肿瘤生物学的统计学显着变化与司他那昔的作用机制一致。该公司表示，正在进行额外的司他那昔临床试验，并将于2024年第三季度公布其原发性胆汁性胆管炎的2期临床试验，并预计由研究者主导的特发性肺纤维化2期临床试验将于2024年第四季度提供最新数据。

.

.

For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News

有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股